Plasma levels of p53 protein and chromosomal aberrations in patients with psoriasis treated with the Goeckerman regimen. 2009

L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
Institute of Pathological Physiology, Faculty of Medicine, Charles University, Hradec Kralove, Prague, Czech Republic. borka@lfhk.cuni.cz

The Goeckerman regimen (GR) is one of the oldest effective treatments for psoriasis. It involves daily dermal application of crude coal tar with dermal exposure to ultraviolet (UV) radiation. A study was carried out to evaluate the genotoxic risk of GR by comparing p53 protein plasma level and chromosomal aberrations (CA) in peripheral lymphocytes in 33 patients with psoriasis, before and after GR. Psoriasis Area and Severity Index (PASI) was used to evaluate the efficacy of GR. PASI significantly decreased after GR (P < 0.001), confirming the excellent efficacy of the treatment, However, significant increases in level of p53 protein (P < 0.05) and CA (P < 0.001) after treatment indicates that this method carries an increased genotoxic risk in patients with psoriasis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D003033 Coal Tar A by-product of the destructive distillation of coal used as a topical antieczematic. It is an antipruritic and keratoplastic agent used also in the treatment of psoriasis and other skin conditions. Occupational exposure to soots, tars, and certain mineral oils is known to be carcinogenic according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) (Merck Index, 11th ed). Clinitar,Estar,Tar, Coal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
January 2021, Acta medica (Hradec Kralove),
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
April 1978, The British journal of dermatology,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
October 2006, Archives of dermatological research,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
July 1983, Journal of the American Academy of Dermatology,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
July 2013, Journal of visualized experiments : JoVE,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
January 1989, International journal of cancer,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
February 1980, Cutis,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
August 1979, The Journal of investigative dermatology,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
April 1981, Canadian Medical Association journal,
L Borska, and C Andrys, and J Krejsek, and K Hamakova, and J Kremlacek, and D Ranna, and L Kotingova, and Z Fiala
January 1979, Indian journal of dermatology, venereology and leprology,
Copied contents to your clipboard!